You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康希诺生物(06185.HK)澄清称与加拿大国家研究委员会的合作并未终止
格隆汇 08-27 22:51

格隆汇8月27日丨康希诺生物(06185.HK)公告,公司注意到部分媒体有关重组新型冠状病毒疫苗(腺病毒载体)加拿大临床试验的误导性报导。

为免对公司股东及潜在投资者产生误导,公司谨此作出以下澄清及声明:截至本公告发布之日,加拿大国家研究委员会与公司的合作并未终止。于最近一段时间内,公司管理层均未接受任何与Ad5-nCoV在加拿大临床试验相关的采访;及公司目前正在与多个国家共同推动Ad5-nCoV的国际多中心III期临床试验。

除本公告所披露者外,经就公司作出一切合理查询后,公司董事会确认其并无知悉根据香港法例第571章证券及期货条例第XIVA部项下内幕消息条文及香港联合交易所有限公司证券上市规则第13.09条须披露的任何内幕消息。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account